CAPRICOR THERAPEUTICS, INC. Logo

CAPRICOR THERAPEUTICS, INC.

Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.

CAPR | US

Overview

Corporate Details

ISIN(s):
US14070B3096
LEI:
Country:
United States of America
Address:
10865 ROAD TO THE CURE, 92121 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics and biologics. The company's scientific platform is centered on its multi-stage pipeline exploring allogeneic cardiosphere-derived cells (CDCs) and exosome science. Capricor aims to create a new class of medicines to treat and prevent a broad range of serious and rare diseases with significant unmet medical needs, including a primary focus on Duchenne muscular dystrophy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CAPRICOR THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CAPRICOR THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CAPRICOR THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FATE THERAPEUTICS INC Logo
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America FATE
FENNEC PHARMACEUTICALS INC. Logo
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America FENC
FibroBiologics, Inc. Logo
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America FBLG
FIBROGEN INC Logo
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America FGEN
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America FLGC
Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America GUTS

Talk to a Data Expert

Have a question? We'll get back to you promptly.